Project Grant K24AI190345
Award Date 9/3/25
Completion Date 8/31/30
Dollars Obligated $206K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Washington, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $862,398 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Fred Hutchinson Cancer Center in Seattle, WA. The grant, running from August 1, 2025 to July 31, 2030, will support research to selectively target and eliminate the HIV/SIV reservoir in T follicular helper cells using novel anti-PD-1 chimeric antigen receptor (CAR) T cells. The research aims to develop safer and more...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $448,573 Project Grant under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) to the Fred Hutchinson Cancer Center in Seattle, Washington. This grant will fund the development of analytical tools to address challenges in vaccine efficacy (VE) trials, such as diverse baseline immunity in target populations and the impact of emerging variants. Key objectives include creating an...
- This $300,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a GMP-compliant E. coli dihydrofolate reductase (EDHFR) vector. This vector will be used to monitor the biodistribution and trafficking of investigational chimeric antigen receptor (CAR) T cell therapies through positron emission tomography (PET) imaging. The goals are to provide a...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $857,346 Project Grant under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) to the Fred Hutchinson Cancer Center. The grant, awarded on January 17, 2025, supports research to define the activating and inhibitory signals in the form of cytokines and metabolites that are present in healthy and infected human tissues to regulate the effector function of CD8 T cells. This research aims to...
- This $220,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) will support research at the Fred Hutchinson Cancer Center in Seattle, Washington. The project aims to use a novel cell lineage tracing method called ASAP-seq to identify and characterize HIV-specific memory natural killer (NK) cells in a cohort of HIV-infected women. This will help elucidate the role of NK...
- This $108,115 Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855), supports comprehensive characterization of lentiviral vector (LVV) integration and impact on host cell biology using novel genomic technologies. The research aims to provide a deeper understanding of LVV integration patterns and cellular transformation, which has emerged as a critical safety...
- This $858,186 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) supports a research project titled "Decoding T Cell Clonotypes, Biology and Predictive Biomarkers Associated with Immune Checkpoint Myocarditis." The project aims to investigate the mechanisms underlying immune-related myocarditis, a potentially fatal adverse event associated with immune checkpoint inhibitor cancer therapies. Using...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $306,500.00 to Mink Therapeutics Inc. to advance a novel cellular immunotherapy product, Agent-797, composed of invariant natural killer T (iNKT) cells. The goal is to evaluate Agent-797's efficacy in reducing graft-versus-host disease (GVHD) and improving immune engraftment for hematopoietic stem...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $307,091 Project Grant to Aleutian Therapeutics, Inc. under the Allergy and Infectious Diseases Research (CFDA 93.855) federal grant program. The objective of this Phase I research is to develop immune evasive strategies for allogeneic (non-self) cell replacement therapies, specifically by ascertaining the minimal number of genetic edits required to enable human pluripotent stem cells to overcome xenogeneic...
- This federal Project Grant award of $1,442,898.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to study the effects of vaccination on outcomes of acute and post-acute respiratory viral infections, including COVID-19, in solid organ transplant recipients. The research aims to better understand the risks of severe respiratory viral infections and associated post-acute syndromes...